Ares Life Sciences to Acquire Antigen Laboratories, Inc., in the United States
News Apr 15, 2013
Ares recently signed an agreement to acquire Greer Laboratories, Inc. a leader in U.S. allergy immunotherapy (AIT) market. The acquisition of Antigen Laboratories is a continuation of Ares' strategic focus on the U.S. AIT market. It is also the majority shareholder of the French based Stallergenes S.A., a pioneer and leader in immunotherapy treatments by sublingual administration. Ares believes there is significant growth potential in the AIT business globally, particularly in the US which currently only represents 10% of the European market and is expected to grow significantly over the next few years.
Jacques Theurillat, CEO of Ares Life Sciences, commented: "As an FDA licensed manufacturer, Antigen has one of the most comprehensive offerings of allergenic extracts in the United States and has a long track record of serving the needs for the ENT specialists. We view the acquisition of Antigen as very complementary to our other investments in the allergy market."
Theron E. Odlaug, Planet Biopharmaceuticals Executive Chairman and CEO, commented, "We are looking forward to becoming a member of the Ares portfolio of life science companies and the resources they will provide to help us continue to grow."
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.